When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

Guggenheim Securities adjusted its financial outlook for Novo Nordisk (NYSE:NVO) shares (NOVOB:DC) (NYSE: NVO), raising the price target slightly to DKK798.00 from DKK795.00. The firm maintained a Buy ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

Novo Nordisk's (CO:NOVOb) top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a... Investing.com – Denmark stocks were lower after ...

2024 The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes drug Victoza, clearing the way for the launch of another copy of the ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...